
|Videos|July 1, 2020
Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors
Author(s)Targeted Oncology
Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Alert-Based ePRO Monitoring Reduces Fatigue in Metastatic Breast Cancer
3
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5

































